[Pleuropulmonary manifestations of rheumatoid arthritis].
Gayraud
M
M
Service de Médecine Interne, Hôpital International de l'Université de Paris.
Guillevin
L
L
D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D001982:Bronchial Diseases / Q000209:etiology; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D003520:Cyclophosphamide / Q000009:adverse effects; D006801:Humans; D008171:Lung Diseases / Q000209:etiology; D008727:Methotrexate / Q000009:adverse effects; D050607:Organogold Compounds; D010396:Penicillamine / Q000009:adverse effects; D010995:Pleural Diseases / Q000209:etiology; D012140:Respiratory Tract Diseases / Q000209:etiology* / Q000503:physiopathology; D008625:Tiopronin / Q000009:adverse effects
D018501:Antirheumatic Agents; D050607:Organogold Compounds; D003520:Cyclophosphamide; D008625:Tiopronin; D010396:Penicillamine; D008727:Methotrexate